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Ca2+ is the most ubiquitous second messenger in neurons whose
spatial and temporal elevations are tightly controlled to initiate
and orchestrate diverse intracellular signaling cascades. Numerous
neuropathologies result from mutations or alterations in Ca2+ han-
dling proteins; thus, elucidating molecular pathways that shape
Ca2+ signaling is imperative. Here, we report that loss-of-function,
knockout, or neurodegenerative disease–causing mutations in the
lysosomal cholesterol transporter, Niemann-Pick Type C1 (NPC1), ini-
tiate a damaging signaling cascade that alters the expression and
nanoscale distribution of IP3R type 1 (IP3R1) in endoplasmic reticu-
lummembranes. These alterations detrimentally increase Gq-protein
coupled receptor–stimulated Ca2+ release and spontaneous IP3R1
Ca2+ activity, leading to mitochondrial Ca2+ cytotoxicity. Mechanis-
tically, we find that SREBP-dependent increases in Presenilin 1 (PS1)
underlie functional and expressional changes in IP3R1. Accordingly,
expression of PS1 mutants recapitulate, while PS1 knockout abro-
gates Ca2+ phenotypes. These data present a signaling axis that links
the NPC1 lysosomal cholesterol transporter to the damaging redis-
tribution and activity of IP3R1 that precipitates cell death in NPC1
disease and suggests that NPC1 is a nanostructural disease.
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Calcium (Ca2+) is the most-ubiquitous second messenger inneurons. For this reason, spatial and temporal elevations in
cytosolic Ca2+ signals are tightly controlled, with elevations in
cytoplasmic Ca2+ used to initiate and orchestrate a host of di-
verse intracellular signaling cascades fundamentally required for
neuronal development, synaptic plasticity, neurotransmission, and
neuron fidelity (for review, refer to refs. 1, 2). One of the primary
mechanisms to elevate intracellular Ca2+ levels is through release
of Ca2+ from the largest intracellular Ca2+ store, the endoplasmic
reticulum (ER). Ca2+ can be rapidly mobilized from the ER into the
cytoplasm through the Inositol 1,4,5-triphosphate receptor (IP3R), a
ligand-gated Ca2+ channel in the ER membrane. IP3Rs are activated
when cell surface Gq-protein coupled receptors (GqPCR) stimulate
phospholipase C (PLC) to hydrolyze the plasma membrane (PM)
lipid PI(4,5)P2 into soluble IP3, the native agonist of the IP3Rs
(3). IP3Rs are further regulated by phosphorylation, protein–
protein interactions, and local Ca2+ concentrations (3, 4).
Niemann-Pick Type C1 (NPC1) disease is an autosomal reces-
sive lysosomal storage disorder that arises from mutations in the
gene encoding the lysosomal NPC1 protein. This transmembrane
cholesterol transporter facilitates the egress of cholesterol from
the acidic compartment to other cellular membranes with its
loss-of-function resulting in the cellular hallmark of NPC1 disease:
an accumulation of lipids within the lysosome and perturbations in
cellular cholesterol homeostasis. The underlying mechanisms
linking cholesterol dysregulation and lipid accumulation to neu-
rodegeneration are not well understood; however, impaired Ca2+
signaling is a consequence of NPC1 disease mutations (5–7). Given
that dysfunctional Ca2+ signaling is a common feature in neuro-
degenerative disease and is thought to precede and contribute to
neuronal cell death (2, 8), understanding the link between NPC1
function and intracellular Ca2+ becomes imperative.
There are three IP3R isoforms: IP3R Type 1 (IP3R1), Type 2,
and Type 3, each with its own differential expression across cell
types and tissues. IP3R1 protein is most abundantly expressed in
soma and synaptic regions of the brain, including Purkinje cells
of the cerebellum (9), the most impacted cell type in NPC1 disease
(10). Functionally, IP3R1 is essential for a variety of intracellular
events including GqPCR signaling (11), synaptic strengthening
(12), Ca2+-dependent gene transcription (11), and Ca2+ transfer
at ER–mitochondrial membrane contact sites (MCS) (13). Be-
haviorally, IP3R1
−/− mice die in utero or only live for a few weeks
while exhibiting severe neurological symptoms such as ataxia and
seizures (14), while specific cerebellum loss (15) or disease mu-
tations in the IP3R1 gene lead to ataxias (16, 17) and Gillespie
syndrome (18). Given IP3R1’s importance in neurological function
and development, and our previous reports of decreased PI(4,5)P2
levels (precursor of IP3) as well as reductions in ER Ca
2+ (source
of GqPCR Ca
2+) in multiple models of NPC disease (19, 20), we
hypothesized that IP3R signaling may be perturbed in NPC1
disease.
Using a combination of murine and patient disease models of
NPC1 disease, we show that despite reduced PI(4,5)P2 (19) and
ER Ca2+ (20), IP3-mediated Ca
2+ release is paradoxically in-
creased. We determine that loss of NPC1 function results in larger
and more numerous immobile IP3Rs clusters near the PM that
drive spontaneous Ca2+ release events (Ca2+ puffs) and prime
IP3R to release more Ca
2+ during GqPCR activation. The cel-
lular consequences of enhanced IP3R clustering and activity are
1) decreased ER Ca2+ levels, 2) increased nuclear factor of ac-
tivated T-cells (NFAT) signaling, and 3) increased mitochondrial
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Ca2+, which leads to neuronal Ca2+ cytotoxicity. We propose that
the lysosomal NPC1 cholesterol transporter can tune the distri-
bution and activity of IP3R in health, while its loss of function,
such as in NPC1 disease, initiates a pervasive signaling cascade
that triggers mitochondrial cytotoxicity.
Results
Loss of NPC1 Function Potentiates Gq-Mediated Ca
2+ Signaling. We
have previously reported that both ER-Ca2+ stores and PM PI(4,5)
P2 levels are significantly reduced in NPC1 disease (19, 20). Given
that IP3R-mediated Ca
2+ release requires both a steep Ca2+ gra-
dient across the ER and IP3’s precursor, PI(4,5)P2; (Fig. 1A), we
tested the hypothesis that cytosolic Ca2+ signals evoked from
IP3Rs following activation of a GqPCR were perturbed in NPC1
loss-of-function cells. First, we compared GqPCR responses from
control and U18666A-treated (U18; specific inhibitor of NPC1)
(21) tsA201 cells loaded with the cytosolic Ca2+ indicator Fluo-4
and treated with histamine, an agonist for the Gq-coupled his-
tamine H1 receptor, in a Ca
2+-free solution to eliminate extracel-
lular Ca2+ contribution. Analysis of the resulting Ca2+ responses
revealed that overnight inhibition of NPC1 significantly increased
the amount of Ca2+ released into the cytoplasm (Fig. 1 B and C).
Similar results were observed from NPC1−/− cells (Fig. 1 D and
E) and patient fibroblasts harboring the most prevalent patient
mutation (NPC1I1061T; Fig. 1 F and G). To confirm that NPC1-
dependent increases in GqPCR-mediated Ca
2+ release were
conserved in neurons, we performed similar experiments in two
murine models of NPC1 disease: 1) NPC1 knockout (NPC1−/−)
neurons and 2) Npc1tm(I1061T)Dso (hereafter referred to as
NPC1I1061T) neurons, which recapitulate the pathological fea-
tures of the most prevalent human disease allele (22). Similar to
cell models, both NPC1−/− (Fig. 1 H and I) and NPC1I1061T
(Fig. 1 J and K) neurons exhibited significantly larger elevations
in Ca2+ following GqPCR stimulation as compared to wild type
(WT) control neurons. Thus, across all models of NPC1 disease,
including primary neurons, IP3R-mediated Ca
2+ release was
significantly increased.
NPC1 Inhibition or Disease Mutation Alters IP3R1 Expression and
Distribution. To determine the molecular mechanism(s) under-
lying increased GqPCR-induced Ca
2+ release, we first measured
mRNA levels from each of the PM elements along the GqPCR
signaling cascade from receptors to PLC enzymes (SI Appendix,
Fig. S1 A and B). Quantification of gene transcripts from control
and NPC1I1061T patient cells revealed that several varieties of
receptor, Gαq, and PLC isoforms were unaltered following loss
of NPC1 function. The sole exception was PLCβ2, which had
elevated messenger ribonucleic acid (mRNA) levels (SI Appendix,
Fig. S1B) but unaltered protein levels (SI Appendix, Fig. S1C) in
NPC1I1061T cells relative to control. Based on these analyses, the
observation that three different GqPCR agonists (histamine, puri-
nergic, and muscarinic) all resulted in enhanced Ca2+ release
(Fig. 1 B–K), and our previous determination that PM PI(4,5)P2
is decreased in NPC1 disease (19) suggest that the molecular
element(s) responsible for enhancing GqPCR signaling in NPC1
disease cells do not lie at the PM.
We next examined whether elements downstream of PI(4,5)P2
are involved in potentiating GqPCR Ca
2+ release in NPC1 cells.
To begin, we analyzed IP3R1, as it is 1) the most common iso-
form in the brain and 2) abundantly expressed in Purkinje cells of
the cerebellum (9), the most vulnerable neuronal cell type in NPC
(23). Western blot analysis determined that NPC1I1061T patient
cells had a 2.6-fold increase in protein levels compared to control
(Fig. 2A). To test whether this expressional change in IP3R1 protein
levels translates to a functional role in potentiating GqPCR Ca
2+








Fig. 1. GqPCR Ca
2+ release is enhanced in NPC1 disease. (A) GqPCR signaling pathway. (B) Average time series of Fluo-4 loaded control (black) and U18-
treated (red) tsA201 cells treated with UTP (100 μM). (C) Quantitative analysis of the UTP-evoked Ca2+ area under the curve (AUC). (D and E) Same as B and C,
only NPC1−/− cells. (F and G) Same as B and C, only control and NPC1I1061T patient cells and treated with histamine (100 μM). (H and I) Same as B and C, only
NPC1−/− neurons treated with Oxo-M. (J and K). Same as B and C, only NPC1I1061T neurons treated Oxo-M. All the data are expressed as mean ± SEM from
individual cells. Statistical analysis was an unpaired t test. ***P < 0.001; ****P < 0.0001.
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kidney 293 (HEK) cells with U18 and evoked IP3R-mediated
Ca2+ release using the purinergic receptor agonist, UTP (100 μM)
(24). Unlike overnight U18 treatment in control cells (Fig. 1B), we
found that incubating IP3R1
−/− cells with U18 did not alter GqPCR
Ca2+ responses (Fig. 2 B and C). These data support a model
wherein increased IP3R1 protein levels facilitate augmented
IP3R-mediated signaling following NPC1 dysfunction.
The spatial distribution of IP3Rs influences ER Ca
2+ release,
inactivation, wave propagation, and oscillations (3, 25–27). To
determine whether increased protein levels alter the spatial or-
ganization of IP3R1, we took several complementary fluorescent
approaches to visualize the endogenous distribution of IP3R1 in
isolated cells, including neurons, and intact brain slices. To be-
gin, we used HeLa cells with endogenous IP3R1 tagged with a
monomeric eGFP (eGFP-IP3R cells) (28). eGFP-IP3R cells allow
us to quantify the endogenous distribution of the IP3R1 without
influence from overexpression or off-target binding of immuno-
fluorescent antibodies. Total internal reflection fluorescence (TIRF)
microscopy, to visualize IP3R1 close to the PM, revealed that
U18 treatment increased both the area and number of IP3R1
clusters close to the PM (Fig. 2 D and E). To independently
confirm that loss of NPC1 function alters IP3R1 distribution near
the PM, we performed immunofluorescence experiments on
patient fibroblasts, neurons, and brain slices from the NPC1I1061T
murine model using a validated IP3R1 antibody (SI Appendix,
Fig. S2 A–D). TIRF imaging from patient fibroblasts determined
that NPC1 disease mutations also increase IP3R1 cluster size and
number (Fig. 2 F and G). Similarly, IP3R1 cluster intensity and
area was increased at both the soma and neurites of isolated hip-
pocampal (Fig. 2 H and I) and cortical neurons (Fig. 2 J and K).
Finally, to ensure that 1) IP3R1 clustering occurs in intact brain
regions and 2) increased IP3R1 cluster size occurs in brain regions
affected by NPC1 disease, cerebellar slices from age-matched wild-
type and symptomatic NPC1I1061T animals were fixed and double
immunostained for IP3R1 and the Purkinje cell marker calbindin.
In agreement with our single-cell data, IP3R1 clusters within the
Purkinje cell soma was significantly larger in NPC1 disease cer-
ebellar sections than controls (Fig. 2L). Collectively, these data
present strong evidence that loss of NPC1 function increases
expression and distribution of IP3R1 to enhance cluster size and
increase GqPCR-mediated Ca
2+ release.
Nanoscale Distribution of IP3R1 Is Altered in NPC1 Disease. Having
demonstrated that IP3R1 clustering and distribution is altered
near the PM in NPC1 disease using diffraction-limited approaches,
we next wanted to precisely map and quantify the nanoscale orga-
nization of IP3R1 at the PM using superresolution single-molecule
localization microscopy in TIRF mode (superresolutionTIRF; reso-
lution is approximately 20 nm) (29). This is important, because it
allows us to investigate the nanoscale molecular architecture within
and between IP3R1 clusters to determine whether they are altered
in NPC1 disease cells.
Quantitative analysis of superresolutionTIRF localization maps
from control and U18-treated eGFP-IP3R cells revealed that
similar to diffraction-limited images, NPC1 inhibition resulted in
an increase in both IP3R cluster size and density (Fig. 3 A and B).
Similar results were also obtained from neurons (Fig. 3 C and D).
During analysis of localization maps, we noticed that single IP3R1
clusters visualized using conventional TIRF microscopy actually
consisted of many discrete puncta when imaged with superresolution
microscopy (SI Appendix, Fig. S3 A–E). Cells lacking NPC1 function
displayed a higher density of puncta in these discrete localized
areas (SI Appendix, Fig. S3 D–F). Further, nearest-neighbor
analysis measuring the distance from both a centroid and pe-
rimeter (SI Appendix, Fig. S3C) of these discrete puncta indi-
cated that puncta were more closely associated with one another
in U18-treated cells (SI Appendix, Fig. S3 G–J). Together, these
data present evidence that loss of NPC1 function not only increases
IP3R puncta size but also increases the density of IP3R1 puncta
both within and between a cluster in NPC1 disease.
IP3R1 Cluster Mobility and Activity Are Increased in NPC1 Disease.
Given that IP3R1 cluster size is increased in NPC1 disease, we
wanted to determine whether the mobility of IP3R1 in the ER
was altered. To this end, we used fluorescent recovery after pho-
tobleaching to quantify the mobility of eGFP-tagged IP3R1 clus-
ters both near the PM (SI Appendix, Fig. S4 A–C) and within the
cell interior (SI Appendix, Fig. S4 D–F). Fitting of fluorescence
recovery kinetics after photobleaching revealed that the mobile
fraction of IP3R1 in U18- treated eGFP-IP3R cells was signifi-
cantly reduced compared to vehicle controls both near the PM (SI
Appendix, Fig. S4C) and near the middle of the cell (SI Appendix,
Fig. S4F).
Recently, it has been reported that immobile IP3R1 clusters
localized close to ER–PM junctions are optimally positioned to
respond to receptor-generated IP3 to initiate Ca
2+ signals (28).
Further, immobile IP3R clusters have been observed to be the
site of spontaneous localized Ca2+ release from the ER, termed
“Ca2+ puffs” (28), with the activity of puffs further influenced by
the number of IP3R within the originating cluster (25, 30). Given
that IP3R1 clusters are larger, contain more discreet IP3R1 puncta
within a cluster, and are more immobile following NPC1 dys-
function, we wanted to determine whether spontaneous Ca2+ puffs
were altered. First, we loaded eGFP-IP3R cells with the Ca
2+ dye
Calbryte590 and simultaneously measured IP3R1 distribution and
spontaneous Ca2+ activity. This approach allows us to measure and
correlate Ca2+ activity in the same region as IP3R1 (Fig. 4A). We
define this signal simply as Ca2+IP3R1, because 1) the Ca
2+ signal
originates within the same location as IP3R1, 2) is sensitive to the
IP3R antagonist Xestospongin C (SI Appendix, Fig. S5 A and C),
and 3) spontaneous Ca2+ signals occur in the absence of extra-
cellular Ca2+ (SI Appendix, Fig. S5B). We do acknowledge the
possibility that these Ca2+ signals may not only result from
IP3R1 but represent a convolved signal from other Ca
2+ sources.
That being said, analysis of spontaneous Ca2+IP3R1 signals deter-
mined that the amplitude, duration, and number of spontaneous
Ca2+ events were all significantly elevated in U18-treated cells
relative to control (Fig. 4 B and C), consisted with previous reports
of increased spontaneous activity with larger IP3R clusters.
To test whether disease mutations exhibit altered Ca2+IP3R1,
we loaded control and NPC1I1061T patient fibroblasts with Fluo-4
and measured spontaneous Ca2+ activity. Similar to U18-treated
cells, NPC1I1061T cells also had increased amplitude, duration,
and mass (volume) of Ca2+ puffs compared to healthy controls
(Fig. 4 D–I). To further investigate a role for IP3R1 in facilitating
these increases in Ca2+ activity, we treated control and IP3R1
−/−
cells with U18 or vehicle control and quantified spontaneous Ca2+
events. We found that treatment with U18 recapitulated the Ca2+
puff phenotype observed in eGFP-IP3R cells and NPC1
I1061T fi-
broblasts, while IP3R1
−/− cells were insensitive to the U18 (Fig. 4 J
and K). Peak fluorescence of Ca2+ puffs was also quantified
showing no significant difference between vehicle and U18 treat-
ment in both cell types but a significant reduction in IP3R1
−/− cells
(Fig. 4L). These results indicate that the altered nanoscale distri-
bution of IP3R1 contribute to enhanced Ca
2+ puff activity in
NPC1 disease.
Presenilin 1 Alters IP3R1 Distribution and Function in NPC1 Disease.
Having established that GqPCR-mediated Ca
2+ signaling, IP3R1
distribution, and IP3R1 activity are all severely altered in NPC1
disease, we next wanted to identify the underlying mechanism(s)
responsible for these changes. Recently, we have reported that
increases in full-length, holoprotein, Presenilin 1 (PS1) expression is
involved in mediating decreases in ER Ca2+ in NPC1 disease (20).
Further, Alzheimer’s disease mutations in PS1 (PS1D257A) that shift
expression mostly to the holoprotein form have previously been
Tiscione et al. PNAS | 3 of 12
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Fig. 2. IP3R1 expression and distribution is remodeled in NPC1 disease. (A, Top) representativeWestern blot of IP3R1 in control and NPC1
I1061T disease fibroblasts.
(Bottom) Quantification of IP3R1 protein expression, normalized to β-Actin. (B) Average time series of Fluo-4 loaded control (black) and IP3R1−/− (red) HEK cells,
treated with UTP. (C) Quantitative analysis of the UTP-evoked Ca2+ area under the curve (AUC). (D, Top) Schematic of TIRF imaging. (Bottom) Representative TIRF
images from eGFP-IP3R HeLa cells, treated with vehicle (Left) or U18 (Right). (E, Left) Quantification of average IP3R puncta area. (Right) IP3R density. (F) Rep-
resentative TIRF images from control (Left) and NPC1I1061T (Right) patient fibroblasts fixed and stained for IP3R1. (G) Quantification of IP3R1 cluster area (Left) and
density (Right) from patient fibroblasts. (H) Representative images from cell body (Left) and neurite (Right) regions of control (Top) and U18-treated (Bottom)
hippocampal neurons fixed and stained for IP3R1 and MAP2. (I) Quantification of IP3R1 intensity. (J) Schematic of TIRF image in neuron. (K) Representative images
from control (Left) and U18-treated (Right) cortical neurons fixed and stained for IP3R1. Insets show zoomed regions containing IP3R1 clusters. (Right) Quanti-
fication of IP3R1 cluster area. (L) Representative cerebellar sections from wild-type (Top) and NPC1
I1061T brains fixed and stained for calbindin and IP3R1. All the
data are expressed as mean ± SEM from individual cells. Statistical analyses were unpaired t tests. ns: not significant; ***P < 0.001; ****P < 0.0001.
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reported to interact and produce exaggerated gain of function
alterations to the biophysical gating properties of IP3Rs (31, 32).
To interrogate a role for PS1 in tuning IP3R1 distribution/func-
tion, we first transfected HeLa cells with HA-PS1 (HA-PS1-WT)
or HA-tagged PS1D257A and treated overnight with either vehicle
control or U18 (10 μM; Fig. 5 A and B). TIRF imaging revealed
that PS1-WT formed discrete clusters close to the PM, with
cluster area significantly increased following overnight treatment
with U18 to inhibit NPC1 function (Fig. 5 A and B). Interestingly,
the PS1D257A mutation also clustered close to the PM and dis-
played a similar mean cluster size as the PS1-WT group treated
with U18 (Fig. 5 A and B). Treatment of PS1D257A-expressing cells
with U18 did not further increase PS1 cluster area (Fig. 5B). These
data suggest that loss of NPC1 function or Alzheimer’s disease
mutations increase the size of PS1 clusters near the PM. To test
whether these increases correlate with changes in IP3R1 distri-
bution, we expressed the aforementioned constructs in eGFP-
IP3R1 HeLa cells and calculated Pearson’s correlation coeffi-
cients. Image analysis revealed that U18 treatment significantly
increases the colocalization of PS1 to IP3R1 (compare Fig. 5 C
and D), while the PS1D257A mutant also colocalizes more with
IP3R compared to wild-type PS1 even in the absence of NPC1
inhibition (Fig. 5E; analysis in Fig. 5F). These data are consistent
with published observations that PS1 physically interacts with
IP3R1 and suggests there is a strong correlation between PS1
cluster size and IP3R1 distribution. To test whether the full-length
form of PS1, which is increased in NPC1 disease (20), alters IP3R1,
we overexpressed PS1D257A in eGFP-IP3R1 HeLa cells. Aligned
with a key role for the holoprotein in mediating the distribution/
function of IP3R1, expression of PS1
D257A increased both IP3R1
clusters (Fig. 5 G and H) and GqPCR-mediated Ca
2+ release
(Fig. 5 I and J) to a similar extent as disease mutations or inhibition
of NPC1. Altogether, these results suggest that enhanced PS1 cluster
size may be responsible for altered nanoscale distribution/func-
tion of IP3R1 following NPC1 loss of function.
A key question remained whether Ca2+ potentially coming
through PS1 (33) can contribute to increases in IP3R1, or whether
only physical interactions (31) between the two proteins are im-
portant. To begin answering this question, we treated eGFP-IP3R1
cells with the Sacro/ER Ca2+-ATPase (SERCA) inhibitor Thap-
sigargin or the Ca2+ chelating agent EGTA in a 0-mM, Ca2+-
containing extracellular solution (SI Appendix, Fig. S6 A–D) and
quantified IP3R1 clusters near the PM over a period of 60 mins.
Under each of these cytoplasmic Ca2+-altering conditions, IP3R1
cluster size significantly decreased near the PM, independently of
alterations in the cell footprint (SI Appendix, Fig. S6 E–M). Thus,
although modulating cytoplasmic Ca2+ concentrations does alter
IP3R1 clustering near the PM, it is in the opposing direction
compared to loss of NPC1 function.
Next, to test a direct role for PS1 driving IP3R1 alterations in
NPC1 disease, we knocked-down or knocked-out PS1 in differ-
ent cells and measured IP3R1 distribution, activity, and GqPCR-
mediated Ca2+ release. First, using small interfering RNA
(siRNA) directed against PS1 in eGFP-IP3R1 HeLa cells, which
decreases PS1 protein levels by 75% (20), we determined that
IP3R1 cluster areas were refractory to U18 treatment (Fig. 6 A
and B). Second, aligned with its ability to normalize IP3R1 clusters


















































































































































Fig. 3. Nanoscale distribution of IP3R1 is remodeled in NPC1 disease. (A, Left) Representative TIRF images of Vehicle (Top) and U18-treated (Bottom) eGFP-
IP3R HeLa cells fixed and immunostained with an anti-GFP antibody. (Right) Superresolution localization map from the same cell. Zoomed regions are from
white solid rectangles. (B) Quantification of density and area of eGFP-IP3R1. (C and D) Same as A and B, only cortical neurons fixed and stained for IP3R1. All
the data are expressed as mean ± SEM from individual cells. Statistical analyses were unpaired t tests. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001.
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significantly reduced spontaneous Ca2+IP3R1 puffs back to con-
trol levels (Fig. 6C). Third, NPC1I1061T patient cells treated with
siRNA PS1 had similar GqPCR-mediated Ca
2+ release as con-
trol (Fig. 6 D and E). As a final approach, we measured GqPCR-
mediated Ca2+ release from control (PS1+/+) and PS1 knockout
(PS1−/−) mouse embryonic fibroblasts and determined that over-
night U18 incubation increased GqPCR Ca
2+ release in PS1+/+ cells
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Fig. 4. Spontaneous intracellular IP3R1 Ca
2+ signaling is enhanced in NPC loss-of-function cells. (A) Representative maximum intensity projections of eGFP-
IP3R1 (Left) and Calbryte590 (Right) from control (Top) and U18-treated cells. Zoomed regions are taken from white rectangles. (B) Representative time series
of spontaneous Ca2+ puffs in control cells (Top) and U18-treated (Bottom, red lines) cells. (Right) Zoomed time regions taken from dashed black rectangle. (C)
Quantification of amplitude, duration, and number of spontaneous Ca2+ events. (D, Left) Representative maximum intensity projections from control fi-
broblasts loaded with Fluo-4. Zoomed regions are taken from solid yellow squares. (Right) Representative time series of spontaneous Ca2+ activity. (E) Same as
D, only NPC1I1061T patient fibroblasts. (F) Frequency distribution of the amplitude of Ca2+ events from healthy fibroblasts (black) and NPC1I1061T disease fi-
broblasts (red). (G) Same as F, except showing the full-width half-max. (H) Same as F, except showing the duration of Ca2+ events. (I) Same as F, except showing
Ca2+ puff mass. (J) Representative time series of Ca2+ events in control cells (Left) or IP3R1
−/− cells (Right) loaded with Fluo-4 and treated with either U18 (red)
or vehicle control (black). (K) Quantitative analysis of Ca2+ puff area under the curve from the cell types and conditions in J. (L) Same as K, except analyzing
Ca2+ puff peak fluorescence from base. All the data are expressed as mean ± SEM from individual cells. Statistical analyses were unpaired t tests except K and L
which were two-way ANOVAs. ns: not significant; *P < 0.05; **P < 0.01; ****P < 0.0001.
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controls (Fig. 6 G and H). Transfecting PS1−/− cells with PS1-
WT reestablished U-18-mediated increases in GqPCR Ca
2+ release
(SI Appendix, Fig. S7 A and B). Collectively, these data support the
hypothesis that PS1-dependent increases in IP3R1 cluster size drive
puff activity and GqPCR-mediated Ca
2+ release in NPC1 disease.
Previously, we have reported that PS1 levels play a crucial role
in decreasing ER Ca2+ (Ca2+ER) to drive synaptic remodeling of
Purkinje neurons in the cerebellum (20). Given the published role
that PS1 plays in enhancing the biophysical release properties of
IP3R1 (32, 31, 34) and the increases in spontaneous Ca
2+
IP3R1
puffs following loss of NPC1 function reported herein, we asked
whether IP3R1 is downstream of PS1 and involved in decreasing
Ca2+ER in NPC1 disease. To begin, we expressed a genetically
encoded Ca2+ indicator targeted to the cytoplasmic leaflet of the
ER membrane (Fig. 6I; ER-GCaMP3) in patient fibroblasts, U18-
treated tsA cells, or PS1D257A-expressing tsA cells to ask whether
we could measure steady-state Ca2+ER leak. Aligned with pub-
lished data (20), both NPC1I1061T patient cells (Fig. 6J) and U18-
treated tsA201 cells (Fig. 6K) exhibited significantly higher resting
ER-GCaMP3 intensity values, consistent with increased Ca2+ER
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Fig. 5. Inhibition of NPC1 increases PS1 clusters and colocalization with IP3R1. (A) Representative TIRF images of HeLa cells expressing HA-PS1, HA-PS1 +
treated with U18, or HA-PS1D257A. (B) Quantification of PS1 area normalized to footprint. (C, Top) TIRF images of eGFP-IP3R HeLa cells transfected with HA-
PS1-WT. (Bottom) Zoomed regions from solid white squares (Left) and line scan showing distribution of signals (Right). (D) Same as C, only treated with U18.
(E) Same as C, only transfected with HA-PS1D257A. (F) Quantitative analysis showing average Pearson’s correlation coefficients from C–E. (G) Representative
TIRF images from Control (Top) and HA-PS1D257A-expressing eGFP-IP3R HeLa cells. (H) Quantification of IP3R1 puncta intensity and size in control and HA-
PS1D257A-expressing cells. (I) Average time series of Fluo-4 loaded control (black), HA-PS1-expressing (red), and HA-PS1D257A-expressing (orange) tsA201 cells
treated with UTP (100 μM). (J) Quantitative analysis of the UTP-evoked Ca2+ area under the curve. All the data are expressed as mean ± SEM from individual
cells. Statistical analyses were unpaired t tests except (B) and (F ) which were two-way and one-way ANOVAs, respectively. ns: not significant; *P < 0.05;
**P < 0.01; ***P < 0.001; ****P < 0.0001.
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leak following loss of NPC1 function. To probe a role for PS1–
IP3R1 interactions facilitating enhanced Ca
2+
ER leak in NPC1
disease, we performed similar experiments in PS1−/− and IP3R1
−/−
cell lines and discovered that ER-GCaMP3 intensity values were
refractory to U18 treatment under both conditions. These data
suggest that PS1 and IP3R1 are both key players in increasing
Ca2+ER leak in NPC1 disease.
The consequence of increased Ca2+ER leak is a decrease in
free Ca2+ER concentrations in NPC1 loss-of-function cells (20);
thus, we tested the effect of knocking out IP3R1 (Fig. 6O). We
loaded NPC1−/− cells and IP3R1
−/− cells with the cytosolic Ca2+
dye, Fluo-4, and applied the SERCA inhibitor thapsigargin in a
0-mM, Ca2+-containing extracellular solution. Treatment with
thapsigargin gave the expected increase in cytoplasmic fluo-4
intensity from control cells, with NPC1−/− cells having a smaller in-
crease in intensity (20) (Fig. 6 P and Q). Conducting similar exper-
iments in IP3R1−/− cells treated with vehicle control or U18 did not
result in any significantly differences in fluo-4 intensity following
Thapsigargin treatment and provide evidence that increased
PS1–IP3R1 interactions drives decreased Ca
2+
ER in NPC1 dis-
ease (Fig. 6 R and S).
Inhibition of SREBP Prevents Increases in IP3R1 Cluster Size and GqPCR
Ca2+ Following Loss of NPC1 Function. Loss of NPC1 function de-
creases lysosomal to ER cholesterol transport, resulting in de-
pletion of ER membrane cholesterol and subsequent activation
of the sterol regulatory element binding protein (SREBP) path-
way, leading to increased gene expression of SREBP-dependent
targets (35). We have previously reported that increased SREBP
activity in NPC1 loss-of-function cells up-regulates expression of
several Ca2+-handling proteins, including PS1, with inhibition of
the SREBP pathway reversing differential protein expression
along with aberrant ER Ca2+ and SOCE phenotypes (20). Thus,
we wanted to determine whether the SREBP pathway is involved
in the remodeling of IP3Rs and potentiated GqPCR-mediated
Ca2+ release. To begin, we conducted qPCR experiments on
NPC1I1061T cells to determine whether mRNA levels of each
IP3R isoform are altered. Consistent with Western blot data,
mRNA levels for IP3R1, but not IP3R2 or IP3R3, were increased
in NPC1I1061T cells (Fig. 7A). Treating cells overnight with the
SREBP inhibitor, PF-429242 (500 nM), abolished increases in
IP3R1 levels from NPC1
I1061T cells without affecting steady-state
mRNA levels of IP3R2 or IP3R3. Furnished with the information
that PF-429242 can decrease IP3R1 mRNA levels, we next asked
whether PF-429242 treatment rescues IP3R1 cluster size in NPC1
loss-of-function cells. To answer this question, we treated eGFP-
IP3R1 cells with U18, or U18 and PF-429242, before quantifying
IP3R1 clusters using TIRF microscopy (Fig. 7B). Similar to the
observed decreases in mRNA levels, treatment with PF-429242
decreased IP3R1 cluster size back to control levels (Fig. 7C).
Next, we measured GqPCR-mediated Ca
2+ release to test whether
PF-429242-mediated decreases in IP3R1 mRNA and cluster size
would also decrease Ca2+ release. Analysis of intracellular Fluo-4
intensity following application of histamine determined that PF-
429242 reduces the GqPCR evoked Ca
2+ signal in NPC1 fibroblasts
back to healthy fibroblast control levels. Finally, we conducted
GqPCR experiments in SCAP
−/− cells that lack a functional SREBP
pathway (36) and found that U18 treatment resulted in a slight
decrease in Ca2+ release following receptor activation (Fig. 7 F and
G). Therefore, like other Ca2+-handling proteins that are increased
in NPC1 disease, IP3R1 can be normalized back to control levels
following inhibition of SREBP.
IP3R1 Drives Ca
2+-Dependent NFAT Translocation and Cytotoxic
Elevations in Mitochondrial Ca2+ Following Loss of NPC1 Function.
Finally, we wanted to begin elucidating the cellular consequences
of aberrant nanoscale distribution and activity of the IP3R in NPC1
disease. Because alterations in cytoplasmic Ca2+ and IP3R-mediated
Ca2+ release are fundamentally required for many cellular pro-
cesses, we focused on two of these pathways: NFAT signaling
(37) and mitochondrial Ca2+ (13) (Ca2+Mito) to ask whether they
are altered in NPC1 disease.
NFAT proteins are a family of transcription factors who are
phosphorylated and reside in the cytoplasm. Upon IP3R stimu-
lation to simultaneously elevate intracellular Ca2+ concentrations
and deplete Ca2+ER, thereby activating store-operated Ca
2+ entry,
NFATs are dephosphorylated by the Ca2+/calmodulin-dependent
serine phosphatase, calcineurin, and translocate to the nucleus to
become active (Fig. 8A). First, we tested whether steady-state
NFAT distribution is different between control and NPC1I1061T
cells; analysis of fluorescence intensity ratios between the cyto-
plasm and nucleus revealed that NPC1I1061T cells had a small but
significant increase in the proportion of NFAT in the nucleus (Fig. 8 B
and C). A similar distribution was observed in U18-treated cells
(Fig. 8D). To test whether IP3R1 is involved in mediating steady-
state increases in nuclear NFAT in NPC1 loss-of-function cells,
we performed similar experiments in IP3R1
−/− cells. Quantifica-
tion of NFAT cytoplasmic/nuclear intensities from U18-treated
IP3R1
−/− disclosed that NFAT no longer preferentially accumu-
lated in the nucleus at steady-state (Fig. 8D). Next, we tested
whether GqPCR-stimulated NFAT translocation was also dif-
ferent between control and NPC1I1061T patient cells. Time series
analysis revealed that 100-s histamine application, a stimulus that
increases cytoplasmic Ca2+ (Fig. 1F), increased NFAT more quickly
in the nucleus of NPC1I1061T cells relative to control (Fig. 8E). Thus,
there is a correlation between the amount of GqPCR-Ca
2+ re-
lease and NFAT translocation. To probe the involvement of
IP3R1, we repeated experiments in tsA201 cells and IP3R1
−/−
cells treated with U18. Similar to NPC1I1061T patient cells, treatment
of tsA201 cells with U18 significantly increased NFAT translocation
to the nucleus (Fig. 8F), an increase that was completely absent in
IP3R1
−/− cells (Fig. 8G). These experiments provide evidence that
NPC1-dependent increases in IP3R1 increase NFAT signaling in
NPC1 disease.
As a final test to determine the cellular consequences of al-
tered IP3R1 signaling in NPC1 disease, we investigated Ca
2+
Mito
and cell viability. Ca2+ represents a key rheostat that couples
mitochondria biogenetics to cellular demand and is frequently
altered in pathophysiological conditions, including neurodegeneration.
Intimate interactions between VDAC1 on mitochondria mem-
branes and IP3R1 on ER membranes provide the platform for
constitutive IP3R-mediated Ca
2+ release to maintain cellular
bioenergetics to meet cellular demands (38) (Fig. 8H). Given the
importance of IP3R1 in regulating Ca
2+
Mito, we expressed a
genetically encoded Ca2+ indicator targeted to mitochondria
(Mito-RCaMPh1) to ask whether Ca2+Mito is altered following
loss of NPC1 function. Quantification of Mito-RCaMPh1 in-
tensities between cells treated with a vehicle or U18 rvealed that
loss of NPC1 function significantly increased Ca2+Mito (Fig. 8 I
and J). Identical experiments conducted on IP3R1
−/− cells revealed
reduced Ca2+Mito levels compared to control with IP3R1
−/− cells
now being refractory to U18 treatment (Fig. 8J). In parallel, we
asked whether increases in Ca2+Mito, which can be cytotoxic in
neurodegenerative conditions, are accompanied by changes in cell
health. Consistent with this hypothesis, cell viability assays deter-
mined U18-dependent increases in Ca2+Mito correlated with in-
creased cell death (Fig. 8K), an observation that was completely
absent in IP3R1
−/− cells. Collectively, these data suggest that
NPC1-dependent increases in IP3R1 distribution/activity increase
Ca2+Mito cytotoxicity in NPC1 disease and presents the IP3R as a
potential target to slow neurodegeneration.
Discussion
Dysfunction of IP3Rs is a common feature across many neuro-
degenerative diseases (39–41); thus, determining molecular de-
tails regarding their regulation and control is imperative for
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human health. Here, we discover a signaling axis that links the
NPC1 lysosomal cholesterol transporter to the nanoscale distri-
bution and activity of IP3R1 (SI Appendix, Fig. S8). We show that
loss of NPC1 function results in augmented clustering of IP3R1 near
the PM, increased frequency and size of spontaneous Ca2+ puffs from
IP3Rs, and enhanced GqPCR-mediated intracellular Ca
2+ sig-
naling. Upstream of changes in IP3R1 appears to be PS1, with
overexpression of PS1D257A phenocopying the observed changes
in NPC1 disease cells. Mechanistically linking cholesterol egress
from the lysosome to IP3R1-dependent alterations in Ca
2+ is the
SREBP pathway, with inhibition of this transcription pathway re-
storing mRNA levels, IP3R1 cluster size, and GqPCR signaling,
respectively. Functionally, altered IP3R1 distribution/activity leads
to increased steady-state and stimulated Ca2+-dependent NFAT
signaling and Ca2+mito toxicity.
GqPCRs are pivotal purveyors of physiological information,
transducing fluctuations in hormones, growth factors, and neu-
rotransmitters across the PM to stimulate intracellular second
messengers that initiate downstream signaling cascades. In this
study, we determine that the PM-localized elements of GqPCR
signaling cascades, namely receptor, Gq, and PLC, are unaltered
or, in the case of PI(4,5)P2, decreased (19) following loss of NPC1
function. These observations, coupled with decreased Ca2+ER
levels (20), made it surprising to find that both receptor-activated
and spontaneous IP3R1-mediated Ca
2+ responses are amplified in
NPC1 disease cells. This counterintuitive discovery can be rec-
onciled with information that IP3R1 protein abundance, nano-
scale distribution, mobility near the PM, and activity are all enhanced
in NPC1 disease. The degree of spatial, temporal, and allosteric



































































































































































































































































































































Fig. 6. Knocking out PS1 or IP3R1 rescues Ca
2+ defects in NPC1 disease cells. (A) Representative TIRF images from control, U18-treated, and U18-treated +
siRNA PS1 eGFP-IP3R1 cells. Zoomed areas are taken from the solid white squares. (B) Quantification of eGFP-IP3R1 cluster size. (C) Quantification of spon-
taneous Ca2+ activity. (D) Average time series of histamine responses from Fluo-4 loaded control (black), NPC1I1061T(red), and NPC1I1061T + siRNA PS1 (blue)
fibroblasts. (E) Quantitative analysis of the histamine-evoked Ca2+ area under the curve (A.U.C). (F) Average time series of UTP responses from Fluo-4 loaded
PSEN+/+ MEF cells treated with vehicle control (black) or U18 (red). (G) Same as F, only PS1−/− cells. (H) Quantification of UTP-evoked Fluo-4 signals. (I)
Schematic of genetically encoded ER-GCaMP3 Ca2+ indicator. (J) Quantification of normalized ER-GCaMP3 intensity in patient fibroblasts. (K) Same as L, only
tsA201 cells treated with U18. (L) Same as K, only tsA201 cells expressing PS1D257A. (M) Same as K, only PS1−/− cells. (N) Same as K, only IP3R1
−/− cells. (O)
Schematic of IP3R1–PS1 hypothesis in NPC1 disease. (P) Average time series of thapsigargin responses from Fluo-4 loaded control (black line) and NPC1
−/− (red
line) cells. (Q) Quantification of area under thapsigargin responses. (R) Same as P, except IP3R1
−/− cells. (S) Same as Q. All the data are expressed as mean ±
SEM from individual cells. B, C, and E were one-way ANOVAs; H was a two-way ANOVA; and J–N, Q, and S were unpaired t tests. ns: not significant; *P < 0.05;
**P < 0.01; ****P < 0.0001.
Tiscione et al. PNAS | 9 of 12
IP3R-driven increases in mitochondrial Ca







































(25, 31, 42); we add another modulatory mechanism for IP3R1
and GqPCR-mediated Ca
2+ release through NPC1 abundance and/
or cholesterol egress across lysosomal–ER MCS. This positions
NPC1 and lysosomal–ERMCS as potential targets to tune GqPCR
signaling with the goal of altering global or local Ca2+ release to
modify neuronal bioenergetics, Ca2+-dependent transcription, or
synaptic plasticity in health or disease.
We detail an important role for PS1 in regulating IP3R1 dis-
tribution and activity following loss of NPC1 function. Under
normal physiological conditions, PS1 undergoes autoproteolytic
cleavage, resulting in two fragments (N and C terminals) that as-
sociate with other proteins to create the γ-secretase complex. Several
mutations in the gene encoding PS1 can abolish this autoproteolytic
activity, keeping PS1 in an uncleaved and full-length state, which is
purported to form Ca2+ leak channels at the ER membrane (33).
Contrasting the hypothesis that PS1 is a Ca2+ leak channel, Cheung
et al. have reported that both Familial Alzheimer’s Disease–linked
PS1 mutations, which lack the ER Ca2+ leak activity, as well as
the catalytically dead PS1 mutants that maintain their full uncleaved
length bind and enhance the gating properties of IP3Rs (31),
suggesting the mechanism of Ca2+ER leak involves physical in-
teractions between PS1 and IP3R1. We find that PS1 and IP3Rs
have little colocalization after overexpression of wild-type PS1;
however, inhibition of NPC1 significantly increased their localiza-
tion with one another. Additionally, overexpression of the catalyti-
cally dead PS1D257A mutation that results in increased full-length
protein form reorganizes IP3R1 nanoscale distribution, spontaneous
puff activity, and GqPCR-mediated Ca
2+ release, independent of
NPC1 inhibition. Finally, IP3R1
−/− cells are refractory to U18 with
no NPC1-dependent Ca2+ phenotypes. This leads us to suggest
that it is the physical interactions between PS1 and IP3R1, coupled
with elevations in cytoplasmic Ca2+ (20), that modify the clus-
tering properties of IP3R1 to enhance their cooperative gating and
thereby their release probability in NPC disease. If this model is
correct, it would position IP3R1-mediated Ca
2+ release as the
distal element underlying enhanced Ca2+ER leak in NPC1 disease.
Questions remain to fully determine the molecular choreography
of PS1–IP3R1 complex, including the following: 1) What is the
optimal stoichiometry of PS1–IP3R1 interactions? 2) Do de-





























































































































Fig. 7. Inhibition or loss of SREBP pathway activity rescues expression and distribution of IP3R1 and Ca
2+ phenotypes in NPC1 disease. (A) Quantification of
ITPR1, ITPR2, and ITPR3 mRNA levels in control (black), control + PF-429242 (gray), NPC1I1061T (red), and NPC1I1061T + PF-429242 (blue) patient fibroblasts. (B)
Representative TIRF images form eGFP-IP3R1 HeLa cells treated with U18 (Left) or U18 and PF-429242. (C) Quantification of IP3R1 cluster size. (D) Average time
series of histamine responses from Fluo-4 loaded control (black line), NPC1I1061T (red line) cells, and NPC1I1061T + PF429242 fibroblasts. (E) Quantification of area
under the histamine responses. (F) Average time series of UTP responses from Fluo-4 loaded control (black line) or U18-treated (red line) SCAP−/− cells. (G)
Quantification of area under the UTP responses. All the data are expressed as mean ± SEM from individual cells. Statistical significance was calculated using the
following test: A, two-way ANOVA; C and G, unpaired t tests; and E, one-way ANOVA. ns: not significant; *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001.
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aggregate, and influence IP3R1? 3) Does decreased ER choles-
terol in NPC1 cells, as evidenced by enhanced SREBP process-
ing (20), reduce cholesterol-dependent partitioning of PS1 and
IP3R1 to allow their increased clustering/interaction? and 4) Are
there other accessory proteins that exert regulatory influence over
this signaling complex?
The SREBP transcription factor appears to link changes in
NPC1 function to alterations in IP3R1 and GqPCR signaling.
Previously, we have reported that the SREBP pathway is involved
in mediating expressional changes in the Ca2+-handling proteins
SERCA, STIM1, ORAI1, and PS1 in NPC1I1061T cells; therefore,
it is perhaps not surprising that the IP3R1 is also influenced by
SREBP. That being said, it is still unknown whether regulation of
IP3R1 by SREBP is through direct or indirect transcriptional
regulation. Further, a key question that remains unanswered is
whether alterations in intracellular Ca2+ signaling are purely del-
eterious sequences (see paragraph below) or are part of a molec-
ular mechanism(s) attempting to correct the cellular phenotypes of
NPC1 disease. There are clear links between elevations in intra-
cellular Ca2+ levels and endocytic fusion and transport events;
further, decreasing Ca2+ER has been reported to redistribute the
intracellular pool of unesterified cholesterol (43) and rescue key
cellular phenotypes of NPC1 disease (6), while knocking out INPP5A
(44) (IP3 5-phosphatase) triggers depletion of cellular cholesterol.
Thus, changes in Ca2+ER signaling may be a key rheostat for main-
tenance and control of cellular cholesterol homeostasis.
Ca2+-handling proteins have been linked to a host of pathol-
ogies, including several neurodegenerative disorders (33, 34).
MCS between the ER and mitochondrial are regions of intimate
membrane apposition that facilitate transport of Ca2+ from the
ER to the mitochondria. Following GqPCR activation or spon-
taneous IP3R opening, Ca
2+ is taken up into mitochondria to
participate in the control of bioenergetics by activating oxidative
metabolism, mitochondrial respiration, and ATP synthesis. No-
tably, dysregulation of Ca2+Mito are potent triggers of necrosis,
apoptosis, and autophagy (for review, refer to ref. 45). Here, we
present evidence that NPC1-dependent increases in IP3R1 distri-
bution and activity increase Ca2+Mito to enhance cell death in NPC1
disease models. Thus, although increased Ca2+ release from the
ER may be initiated as a mechanism to alter cholesterol homeo-
stasis or redistribute toxic metabolites associated with NPC1 disease
mutations, the prolonged elevations in cytoplasmic and Ca2+Mito
could ultimately be a central driver of neuronal cell death in NPC
disease. This presents IP3R1 and MAMs as potential therapeutic
targets to correct Ca2+ phenotypes in order to slow Purkinje neu-
ron neurodegeneration and NPC disease progression.
In conclusion, we characterize a link between the lysosomal NPC1
cholesterol transporter and changes in IP3R-dependent Ca
2+ sig-
naling. We find that differential expressional and localization of
IP3R1 enhances both spontaneous and GqPCR-mediated Ca
2+
release to promote mitochondrial cytotoxicity. This work fur-
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tsA201 Cells IP3RT1-/- CellsPatient Fibroblasts
IP3RT1-/-
IP3RT1-/-
Fig. 8. Knockout of IP3R1 rescues Ca
2+-dependent gene transcription and Ca2+Mito cytotoxicity in NPC1 loss-of-function cells. (A) Schematic of NFAT trans-
location to the nucleus. (B) Representative images from control (Top) and NPC1I1061T (Bottom) fibroblasts expressing NFAT. (C) Quantification of NFAT in-
tensity in the nucleus relative to the cytoplasm in control and NPC1I1061T fibroblasts. (D) Same analysis as C, only using control and IP3R1
−/− cells. (E) Averaged
time series of nuclear NFAT intensity following the addition of Histamine in control (black line) and NPC1I1061T (red line) fibroblasts. (F) Same as E, only UTP
application in control and U18-treated tsA201 cells. (G) Same as F, only using IP3R1
−/− cells. (H) Schematic of Ca2+ transfer at ER–mitochondria MCS. (I)
Representative images of Mito-RCaMP in control (Top) and IP3R1
−/− cells (Bottom) treated with vehicle control (Left) or U18 (Right). (J) Quantification of
normalized Mito-RCaMP intensity in control and IP3R1
−/− cells. (K) Quantification of live cell/dead cell ratio in control and IP3R1
−/− cells treated with vehicle
control or U18. All the data are expressed as mean ± SEM from individual cells. Statistical significance was calculated using the following tests: C, unpaired
t test and D, J, and K, two-way ANOVA. ns: not significant; *P < 0.05; **P < 0.01; ****P < 0.0001.
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signaling, most importantly PS1, whose form and expression are
altered in NPC1 disease. By elucidating these regulatory pathways,
we have provided potential therapeutic targets to address IP3R
dysfunction, a feature of NPC1 disease and other neurodegenerative
disorders.
Materials and Methods
Detailed methods can be found in SI Appendix. Briefly, NPC1I1061T patient
cells, NPC1−/− cells, and tsA201 cells treated overnight with U18666A and
male and female NPC1I1061T mice served as models of NPC disease and were
comparted to control cells in this study. Protein levels were determined us-
ing immunoblot approaches. Ca2+ imaging was performed using an Andor
W1 spinning disk system. Immunofluorescence TIRF, superresolution, and
confocal images were acquired using a Leica single-molecule localization
system or a Zeiss AiryScan confocal microscope.
Data Availability.All study data are included in the article and/or SI Appendix.
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